Women's Health Cluster Drug Development Pipeline Review, 2017

Women's Health Cluster Drug Development Pipeline Review, 2017

Summary


This report provides an overview of the women’s health pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for female infertility, polycystic ovarian syndrome and endometriosis, and also features dormant and discontinued projects.

Infertility is defined as the inability to get pregnant after a year of unprotected intercourse. Female infertility can be also be caused by a number of factors, which include damage to fallopian tubes, hormonal causes, cervical causes, uterine causes, unexplained infertility. There are a total of 87 products in development for this indication, by 47 companies and 11 academic institutions. Key companies operating in this pipeline space include Bayer, Evotec, AlphaMab, Zydus Cadila Healthcare and Ferring.

Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. There are a total of 12 products in development for this indication, by eight companies and three academic institutions. A number of companies are operating in this space, with EffRx alone developing multiple programs within the area.

Finally, endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (the endometrium) grows outside the uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. There are a total of 53 products in development for this indication, by 29 companies and eight academic institutions. Key companies operating in this pipeline space include Bayer and Evotec, which are each developing five distinct programs in this disease area.

Generally the main types of therapy being developed act on hormone receptors, reflecting the hormone-driven pathophysiology of this disease area. However, particularly in polycystic ovarian syndrome, a broader range of molecular targets, such as intracellular protein kinases, chemokine receptors and other cell signaling components are also targeted.

Scope

  • Which companies are the most active within the pipeline for women’s health therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of women’s health therapeutics?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Women's Health Cluster Report Coverage
    • Women Infertility – Overview
    • Polycystic Ovarian Syndrome – Overview
    • Endometriosis – Overview
  • Therapeutics Development
    • Women Infertility
      • Table Figure 1: Number of Products under Development for Women Infertility
      • Table Number of Products under Development for Women Infertility
      • Table Figure 2: Number of Products under Development by Companies, Women Infertility
      • Table Number of Products under Development by Companies, Women Infertility
      • Table Figure 3: Number of Products under Development by Universities/Institutes, Women Infertility
      • Table Number of Products under Development by Universities/Institutes, Women Infertility
      • Table Products under Development by Companies, Women Infertility
      • Table Products under Development by Universities/Institutes, Women Infertility
    • Polycystic Ovarian Syndrome
      • Table Figure 4: Number of Products under Development for Polycystic Ovarian Syndrome
      • Table Number of Products under Development for Polycystic Ovarian Syndrome
      • Table Figure 5: Number of Products under Development by Companies, Polycystic Ovarian Syndrome
      • Table Number of Products under Development by Companies, Polycystic Ovarian Syndrome
      • Table Number of Products under Development by Universities/Institutes, Polycystic Ovarian Syndrome
      • Table Products under Development by Companies, Polycystic Ovarian Syndrome
      • Table Products under Development by Universities/Institutes, Polycystic Ovarian Syndrome
    • Endometriosis
      • Table Figure 6: Number of Products under Development for Endometriosis
      • Table Number of Products under Development for Endometriosis
      • Table Figure 7: Number of Products under Development by Companies, Endometriosis
      • Table Number of Products under Development by Companies, Endometriosis
      • Table Figure 8: Number of Products under Development by Universities/Institutes, Endometriosis
      • Table Number of Products under Development by Universities/Institutes, Endometriosis
      • Table Products under Development by Companies, Endometriosis
      • Table Products under Development by Universities/Institutes, Endometriosis
  • Therapeutics Assessment
    • Women Infertility
      • Table Figure 9: Number of Products by Top 10 Targets, Women Infertility
      • Table Figure 10: Number of Products by Stage and Top 10 Targets, Women Infertility
      • Table Number of Products by Stage and Target, Women Infertility
      • Table Figure 11: Number of Products by Top 10 Mechanism of Actions, Women Infertility
      • Table Figure 12: Number of Products by Stage and Top 10 Mechanism of Actions, Women Infertility
      • Table Number of Products by Stage and Mechanism of Action, Women Infertility
      • Table Figure 13: Number of Products by Routes of Administration, Women Infertility
      • Table Figure 14: Number of Products by Stage and Routes of Administration, Women Infertility
      • Table Number of Products by Stage and Route of Administration, Women Infertility
      • Table Figure 15: Number of Products by Molecule Types, Women Infertility
      • Table Figure 16: Number of Products by Stage and Molecule Types, Women Infertility
      • Table Number of Products by Stage and Molecule Type, Women Infertility
    • Polycystic Ovarian Syndrome
      • Table Figure 17: Number of Products by Top 10 Targets, Polycystic Ovarian Syndrome
      • Table Figure 18: Number of Products by Stage and Top 10 Targets, Polycystic Ovarian Syndrome
      • Table Number of Products by Stage and Target, Polycystic Ovarian Syndrome
      • Table Figure 19: Number of Products by Top 10 Mechanism of Actions, Polycystic Ovarian Syndrome
      • Table Figure 20: Number of Products by Stage and Top 10 Mechanism of Actions, Polycystic Ovarian Syndrome
      • Table Number of Products by Stage and Mechanism of Action, Polycystic Ovarian Syndrome
      • Table Figure 21: Number of Products by Routes of Administration, Polycystic Ovarian Syndrome
      • Table Figure 22: Number of Products by Stage and Routes of Administration, Polycystic Ovarian Syndrome
      • Table Number of Products by Stage and Route of Administration, Polycystic Ovarian Syndrome
      • Table Figure 23: Number of Products by Molecule Types, Polycystic Ovarian Syndrome
      • Table Figure 24: Number of Products by Stage and Molecule Types, Polycystic Ovarian Syndrome
      • Table Number of Products by Stage and Molecule Type, Polycystic Ovarian Syndrome
    • Endometriosis
      • Table Figure 25: Number of Products by Top 10 Targets, Endometriosis
      • Table Figure 26: Number of Products by Stage and Top 10 Targets, Endometriosis
      • Table Number of Products by Stage and Target, Endometriosis
      • Table Figure 27: Number of Products by Top 10 Mechanism of Actions, Endometriosis
      • Table Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions, Endometriosis
      • Table Number of Products by Stage and Mechanism of Action, Endometriosis
      • Table Figure 29: Number of Products by Routes of Administration, Endometriosis
      • Table Figure 30: Number of Products by Stage and Routes of Administration, Endometriosis
      • Table Number of Products by Stage and Route of Administration, Endometriosis
      • Table Figure 31: Number of Products by Molecule Types, Endometriosis
      • Table Figure 32: Number of Products by Stage and Molecule Types, Endometriosis
      • Table Number of Products by Stage and Molecule Type, Endometriosis
  • Companies Involved in Therapeutics Development
    • Women Infertility
      • Table Women Infertility – Pipeline by 4P Therapeutics LLC
      • Table Women Infertility – Pipeline by AbbVie Inc
      • Table Women Infertility – Pipeline by Addex Therapeutics Ltd
      • Table Women Infertility – Pipeline by AlphaMab Co Ltd
      • Table Women Infertility – Pipeline by APAvadis Biotechnologies Srl
      • Table Women Infertility – Pipeline by ASKA Pharmaceutical Co Ltd
      • Table Women Infertility – Pipeline by Astellas Pharma Inc
      • Table Women Infertility – Pipeline by Bayer AG
      • Table Women Infertility – Pipeline by Dong-A Socio Holdings Co Ltd
      • Table Women Infertility – Pipeline by Dongkook Pharmaceutical Co Ltd
      • Table Women Infertility – Pipeline by ElexoPharm GmbH
      • Table Women Infertility – Pipeline by EndoCeutics Inc
      • Table Women Infertility – Pipeline by Enteris BioPharma Inc
      • Table Women Infertility – Pipeline by Evotec AG
      • Table Women Infertility – Pipeline by Ferring International Center SA
      • Table Women Infertility – Pipeline by Forendo Pharma Ltd
      • Table Women Infertility – Pipeline by Glycotope GmbH
      • Table Women Infertility – Pipeline by Isifer AB
      • Table Women Infertility – Pipeline by Kissei Pharmaceutical Co Ltd
      • Table Women Infertility – Pipeline by Lipicard Technologies Ltd
      • Table Women Infertility – Pipeline by Livzon Pharmaceutical Group Inc
      • Table Women Infertility – Pipeline by Luye Pharma Group Ltd
      • Table Women Infertility – Pipeline by Merck & Co Inc
      • Table Women Infertility – Pipeline by Navya Biologicals Pvt Ltd
      • Table Women Infertility – Pipeline by Nippon Shinyaku Co Ltd
      • Table Women Infertility – Pipeline by Nora Therapeutics Inc
      • Table Women Infertility – Pipeline by ObsEva SA
      • Table Women Infertility – Pipeline by Ogeda SA
      • Table Women Infertility – Pipeline by Orphagen Pharmaceuticals Inc
      • Table Women Infertility – Pipeline by Pangen Biotech Inc.
      • Table Women Infertility – Pipeline by Pantec Biosolutions AG
      • Table Women Infertility – Pipeline by PharmaEssentia Corp
      • Table Women Infertility – Pipeline by Philogen SpA
      • Table Women Infertility – Pipeline by Repros Therapeutics Inc
      • Table Women Infertility – Pipeline by Richter Gedeon Nyrt
      • Table Women Infertility – Pipeline by SK Chemicals Co Ltd
      • Table Women Infertility – Pipeline by Takeda Pharmaceutical Company Ltd
      • Table Women Infertility – Pipeline by TocopheRx Inc
      • Table Women Infertility – Pipeline by ValiRx Plc
      • Table Women Infertility – Pipeline by Viramal Ltd
      • Table Women Infertility – Pipeline by Zydus Cadila Healthcare Ltd
    • Polycystic Ovarian Syndrome
      • Table Polycystic Ovarian Syndrome – Pipeline by Addex Therapeutics Ltd
      • Table Polycystic Ovarian Syndrome – Pipeline by Crinetics Pharmaceuticals Inc
      • Table Polycystic Ovarian Syndrome – Pipeline by EffRx Pharmaceuticals SA
      • Table Polycystic Ovarian Syndrome – Pipeline by Millendo Therapeutics Inc
      • Table Polycystic Ovarian Syndrome – Pipeline by Ogeda SA
      • Table Polycystic Ovarian Syndrome – Pipeline by Vicore Pharma AB
    • Endometriosis
      • Table Endometriosis – Pipeline by AbbVie Inc
      • Table Endometriosis – Pipeline by Addex Therapeutics Ltd
      • Table Endometriosis – Pipeline by APAvadis Biotechnologies Srl
      • Table Endometriosis – Pipeline by Astellas Pharma Inc
      • Table Endometriosis – Pipeline by Bayer AG
      • Table Endometriosis – Pipeline by Dongkook Pharmaceutical Co Ltd
      • Table Endometriosis – Pipeline by ElexoPharm GmbH
      • Table Endometriosis – Pipeline by EndoCeutics Inc
      • Table Endometriosis – Pipeline by Enteris BioPharma Inc
      • Table Endometriosis – Pipeline by Evotec AG
      • Table Endometriosis – Pipeline by Forendo Pharma Ltd
      • Table Endometriosis – Pipeline by Kissei Pharmaceutical Co Ltd
      • Table Endometriosis – Pipeline by Lipicard Technologies Ltd
      • Table Endometriosis – Pipeline by Luye Pharma Group Ltd
      • Table Endometriosis – Pipeline by Nippon Shinyaku Co Ltd
      • Table Endometriosis – Pipeline by Ogeda SA
      • Table Endometriosis – Pipeline by Orphagen Pharmaceuticals Inc
      • Table Endometriosis – Pipeline by Philogen SpA
      • Table Endometriosis – Pipeline by Repros Therapeutics Inc
      • Table Endometriosis – Pipeline by SK Chemicals Co Ltd
      • Table Endometriosis – Pipeline by Takeda Pharmaceutical Company Ltd
      • Table Endometriosis – Pipeline by ValiRx Plc
      • Table Endometriosis – Pipeline by Viramal Ltd
  • Dormant Projects
    • Women Infertility
      • Table Women Infertility – Dormant Projects
    • Polycystic Ovarian Syndrome
      • Table Polycystic Ovarian Syndrome – Dormant Projects
    • Endometriosis
      • Table Endometriosis – Dormant Projects
  • Discontinued Products
    • Women Infertility
      • Table Women Infertility – Discontinued Products
    • Polycystic Ovarian Syndrome
      • Table Polycystic Ovarian Syndrome – Discontinued Products
    • Endometriosis
      • Table Endometriosis – Discontinued Products
  • Product Development Milestones
    • Women Infertility
    • Polycystic Ovarian Syndrome
    • Endometriosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook